Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-28T23:42:56.755Z Has data issue: false hasContentIssue false
  • English
  • Français

Anti-inflammatory properties of Risperidone : A clinical Trial

Published online by Cambridge University Press:  19 July 2023

F. Askri ,
A. Aissa ,
S. Jedda ,
A. Ben Chaabene ,
H. Abaza ,
U. Ouali  and
Y. Zgueb
F. Askri*
Affiliation:
1Avicenna, Razi Psychiatric Hospital, Manouba
A. Aissa
Affiliation:
1Avicenna, Razi Psychiatric Hospital, Manouba
S. Jedda
Affiliation:
1Avicenna, Razi Psychiatric Hospital, Manouba
A. Ben Chaabene
Affiliation:
2Biology, Salah Azaiz, Tunis
H. Abaza
Affiliation:
3Biology, Razi Psychiatric Hospital, Manouba, Tunisia
U. Ouali
Affiliation:
1Avicenna, Razi Psychiatric Hospital, Manouba
Y. Zgueb
Affiliation:
1Avicenna, Razi Psychiatric Hospital, Manouba
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The evidence of an inflammatory status at onset of psychosis supports the adjunction of anti-inflammatory agent to antipsychotic (AP). Some negative results of these clinical trials lead us to wonder about the anti-inflammatory power of AP.

Objectives

Would the action of associated anti-inflammatory agents be negligible compared to the anti-inflammatory potential of AP?

Methods

We conducted a prospective study. We included patients hospitalized for acute relapse of schizophrenia. They were all treated with Risperidone. We measured High sensitive C Reactive Protein (Hs CRP) at baseline and 8 weeks after.

Results

We included 24 patients. Mean age was 34,5 +7,32 years with 75% of female. Mean age of onset of illness was 24,63 ±4,81 years and illness duration was 10,70 +6,42 years. After 8 weeks, PANSS scores decreased significantly from 79,13 +12,07 to 47,21 +8,41 and Hs CRP levels dropped by 1,55 +3,96 mg/l.

Conclusions

These results highlighted the anti-inflammatory action of Risperidone. Clinical trial should consider the proportion of anti-inflammatory agents action.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S181 - S182
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.